Shares of Amryt Pharma plc (LON:AMYT – Get Free Report) fell 11.7% during mid-day trading on Thursday . The company traded as low as GBX 143 ($1.79) and last traded at GBX 143 ($1.79). 90,726 shares were traded during mid-day trading, a decline of 81% from the average session volume of 469,552 shares. The stock had previously closed at GBX 162 ($2.03).
Amryt Pharma Price Performance
The business’s fifty day simple moving average is GBX 143 and its 200 day simple moving average is GBX 143. The company has a current ratio of 1.80, a quick ratio of 1.14 and a debt-to-equity ratio of 66.05. The stock has a market cap of £457.11 million and a price-to-earnings ratio of -4.33.
Amryt Pharma Company Profile
Amryt Pharma plc, a commercial-stage biopharmaceutical company, develops and commercializes novel therapeutics to treat patients suffering from serious and life-threatening rare diseases. The company offers Lomitapide for the treatment of homozygous familial hypercholesterolemia; and Metreleptin for the treatment of generalized and partial lipodystrophy.
See Also
- Five stocks we like better than Amryt Pharma
- With Risk Tolerance, One Size Does Not Fit All
- Vertiv’s Cool Tech Makes Its Stock Red-Hot
- 10 Best Airline Stocks to Buy
- MarketBeat Week in Review – 11/18 – 11/22
- Dividend Screener: How to Evaluate Dividend Stocks Before Buying
- 2 Finance Stocks With Competitive Advantages You Can’t Ignore
Receive News & Ratings for Amryt Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amryt Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
